2008 Annual Meeting Abstracts

---

Female Sexual Dysfunction (FSD) In Patients with Painful Bladder Syndrome (PBS): Evaluation of the Use of Elmiron
Stanley Zaslau, Elizabeth T Brown*, Dale Riggs*, Barbara J Jackson*, Stanley J Kandzari
West Virginia University, Morgantown, WV

Introduction: We have previously reported that patients with PBS receiving anti-depressant medication exhibit significantly worse symptom scores employing the Female Sexual Function Index (FSFI) than those taking other medication (ANOVA, p< 0.001). The authors report herein the data on 1300 subjects further indexed by the use of Elmiron and compare the degree of FSD associated with the disease.
Methods: Domain values were obtained by using the FSFI. This 19-item questionnaire evaluated FSD in the following six domains: desire, arousal, lubrication, orgasm, satisfaction, and pain. The respondents were indexed first by the use of anti-depressant medications and the absence of such medication (Control), then further by the use of Elmiron.
Results: : Respondents taking anti-depressant medication and Elmiron exhibited an overall FSFI of 12.12 + 6.05 when compared to those taking anti-depressant medication alone 12.01 + 6.44 (NS). Those taking Elmiron alone reported an overall FSFI of 13.32 + 6.47 compared to those denying the use of both anti-depressant medication and Elmiron 13.18 + 6.12 (NS). The table below further compares these data across the six domains measured by the FSFI.

	Antidepressants Elmiron	Antidepressants No Elmiron		Control Elmiron	Control No Elmiron
FSFI Domains	N = 223 Mean+S.D.	N = 242 Mean+S.D.	P Value	N = 260 Mean+S.D.	N = 575 Mean+S.D.	P Value
Desire	2.19 + 0.99	2.24 + 1.12	NS	2.54 + 1.21	2.39 + 1.16	NS
Arousal	2.68 + 1.61	2.61 + 1.67	NS	2.94 + 1.65	2.89 + 1.65	NS
Lubrication	2.49 + 1.58	2.41 + 1.64	NS	2.72 + 1.93	2.73 + 1.54	NS
Orgasm	2.66 + 1.90	2.58 + 2.03	NS	2.84 + 1.95	2.93 + 1.94	NS
Satisfaction	2.90 + 1.58	2.83 + 1.62	NS	3.00 + 1.62	2.93 + 1.60	NS
Pain	1.86 + 1.41	1.92 + 1.62	NS	2.13 + 1.58	2.22 + 1.62	NS
Overall FSFI	12.12 + 6.05	12.01 + 6.44	NS	13.32 + 6.47	13.18 + 6.12	NS

Conclusions: Elmiron had no effect in the patients taking anti-depressant medication or the control subset of this data. Therefore, Elmiron is ineffective in reducing the degree of FSD in patients suffering from PBS, regardless of anti-depressant therapy use.

---